Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression-Reference-Cited by-同舟云学术

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression

Published:2019-09-01 Issue:9 Volume:76 Page:893
ISSN:2168-622X
Container-title:JAMA Psychiatry
language:en
Short-container-title:JAMA Psychiatry

Author:

Daly Ella J.¹,Trivedi Madhukar H.²,Janik Adam³,Li Honglan¹,Zhang Yun⁴,Li Xiang⁵,Lane Rosanne⁶,Lim Pilar⁶,Duca Anna R.¹,Hough David¹,Thase Michael E.⁷,Zajecka John⁸,Winokur Andrew⁹¹⁰,Divacka Ilona¹¹,Fagiolini Andrea¹²,Cubala Wieslaw J.¹³,Bitter István¹⁴,Blier Pierre¹⁵,Shelton Richard C.¹⁶,Molero Patricio¹⁷,Manji Husseini¹,Drevets Wayne C.³,Singh Jaskaran B.³

Affiliation:

1. Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey

2. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas

3. Department of Neuroscience, Janssen Research and Development LLC, San Diego, California

4. Department of Clinical Biostatistics, Janssen Research and Development LLC, Fremont, California

5. Department of Clinical Biostatistics, Janssen Research and Development LLC, Raritan, New Jersey

6. Department of Clinical Biostatistics, Janssen Research and Development LLC, Titusville, New Jersey

7. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia

8. Department of Psychiatry, Rush University Medical Center, Chicago, Illinois

9. Department of Psychiatry, University of Connecticut Health, Farmington

10. Institute of Living, Hartford, Connecticut

11. Private practice, Prague, Czech Republic

12. Department of Molecular Medicine, Division of Psychiatry, University of Siena, Siena, Italy

13. Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

14. Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

15. Departments of Psychiatry and Cellular/Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada

16. Department of Psychiatry, University of Alabama School of Medicine, Birmingham

17. Department of Psychiatry, Clinica Universidad de Navarra, Pamplona, Spain

Publisher

American Medical Association (AMA)

Subject

Psychiatry and Mental health

Link

https://jamanetwork.com/journals/jamapsychiatry/article-pdf/76/9/893/17851981/jamapsychiatry_daly_2019_oi_190033.pdf

Reference27 articles.

1. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.;Walker;JAMA Psychiatry,2015

2. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.;Rush;Am J Psychiatry,2006

3. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.;Newport;Am J Psychiatry,2015

4. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.;Zarate;Arch Gen Psychiatry,2006

5. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.;Murrough;Am J Psychiatry,2013

Cited by 371 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low-dose Esketamine suppresses NLRP3-mediated apoptotic and pyroptotic cell death in microglial cells to ameliorate LPS-induced depression via ablating GSK-3β;Behavioural Brain Research;2024-02

2. Comparison of dexmedetomidine and a dexmedetomidine-esketamine combination for reducing dental anxiety in preschool children undergoing dental treatment under general anesthesia: A randomized controlled trial;Journal of Affective Disorders;2024-02

3. Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats;Nature Communications;2024-01-30

4. Opioid use disorder: current trends and potential treatments;Frontiers in Public Health;2024-01-25

5. Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada;Frontiers in Psychiatry;2024-01-08